Responses
Clinical and epidemiological research
Concise report
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
Compose a Response to This Article
Other responses
No responses have been published for this article.